1Keystone EC. B cells in rheumatoid arthritis from hypothesis to the clinic. Rheumatology,2005,44:ii8-ii12.
2Weyand CM, Kurtin PJ, Goronzy JJ. Ectopic lymphoid organogenesis: a fast track for autoimmunity.Am J Pathol, 2001,159:787-793.
3Bohnhorst JO, Thoen JE, Natvig JB, et al. Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood B cells in patients with primary Sjogren′s syndrome. Scand J Immunol, 2001,54:421-427.
4Dorner T, Burmester GR. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol,2003,15:246-252.
5Waaler JCW. On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. Acta Pathol Microbiol Scand,1940,17:172-188.
6Bridges SL. Update on autoantibodies in rheumatoid arthritis.Curr Rheumatol Rep,2004,6:343-350.
7Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum,1988,31:99-107.
8Low JM, Moore TL. A role for the complement system in rheumatoid arthritis.Curr Pharm, 2005,11:655-670.
9Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis:II Tcell-independent mechanisms from beginning to end. Arthritis Rheum,2002,46:298-308.
10Nardella FA, Dayer JM, Roelke M,et al. Self-associating IgG rheumatoid factors stimulate monocytes to release prostaglandins and mononuclear cell factor that stimulates collagenase and prostaglandin production by synovial cells. Rheumatol Int,1983, 3:183-186.
2Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am, 2004, 30:393 - 403.
3Pitashny M, Shoenfeld Y. B cell depletion in autoimmune rheumatic diseases. Autoimmun Rev, 2005, 4:436 - 441.
4Perosa F, Favoino E, Caragnano MA, et al. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev, 2005, 4:526 - 531.
5Cerny T, Borisch B, Introna M, et al. Mechanism of action of rituximab. Anticancer Drugs, 2002, 2:3 - 10.
6Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid arthritis synovium is B cell dependent. J Immunology, 2001, 167:4710 - 4718.
7Brodszky V, Czirjak L, Geher P, et al. Rituximab in patients with rheumatoid arthritis: systematic review. Orv Hetil, 2007, 148: 1883 - 1893.
8Popa C, Leandro M J, Cambfidge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford), 2007, 46:626 - 630.
9Edwards JC, Cambridge G. The use of Rituximab in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology, 2001, 40:205 - 211.
10Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B - cell - targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 2004, 350:2572 - 2581.
